Kantonsspital St.Gallen

SOS AMI Selatogrel

Micha T. Maeder, Susanne Vetsch & Karin Fink

Kurzfassung Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction
Art des Forschungsprojektes Klinische Forschung
Status Laufend - Rekrutierungsphase
Projektstart 2022
Projektende 2026
Studiendesign prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, Phase 3 study
Verantwortliche Person / Hauptpr├╝farzt am KSSG Prof. Micha Maeder